Literature DB >> 9111258

Newly acquired herpes simplex virus keratitis after penetrating keratoplasty.

L Remeijer1, P Doornenbal, A J Geerards, W A Rijneveld, W H Beekhuis.   

Abstract

BACKGROUND: After penetrating keratoplasty for reasons unrelated to herpes simplex virus (HSV) keratitis, any nonspecific epithelial defect may still be caused by HSV. The purpose of this study is to determine the incidence of newly acquired herpetic keratitis and to assess contributing factors.
METHODS: The authors retrospectively studied the results of 2398 penetrating keratoplasties performed between 1980 and 1995. Three typical case histories are discussed.
RESULTS: Of 2112 patients in whom the primary diagnosis was not related to HSV keratitis, 18 presented with epithelial herpetic keratitis in their corneal graft. The incidence of newly acquired herpetic keratitis after penetrating keratoplasty was 1.2 per 1000 person-years. In most cases, the infection occurred in the first 2 years after the transplantation. Most often, well-known reactivating stimuli could have caused the HSV infection.
CONCLUSIONS: Herpes simplex virus keratitis may develop after penetrating keratoplasty even without a clinical history of HSV in the host. Thus, HSV should be considered in the differential diagnosis of a postpenetrating keratoplasty epithelial defect. The high incidence of this infection in the first 2 years after such surgery suggests a causal relation between corneal transplantation and the HSV infection.

Entities:  

Mesh:

Year:  1997        PMID: 9111258     DOI: 10.1016/s0161-6420(97)30257-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Human herpesviruses in the cornea.

Authors:  S B Kaye; K Baker; R Bonshek; H Maseruka; E Grinfeld; A Tullo; D L Easty; C A Hart
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 2.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

3.  [Ping-pong transmission of herpes simplex virus 1 following corneal transplantation].

Authors:  E Stavridis; Z Gatzioufas; A Hasenfus; M Sauter; S Smola; B Seitz
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

4.  A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits.

Authors:  Partha S Bhattacharjee; Donna M Neumann; James M Hill
Journal:  Curr Eye Res       Date:  2009-02       Impact factor: 2.424

5.  Graft failure in human donor corneas due to transmission of herpes simplex virus.

Authors:  S Biswas; P Suresh; R E Bonshek; G Corbitt; A B Tullo; A E Ridgway
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

6.  Detection of herpes simplex virus type 1, 2 and varicella zoster virus DNA in recipient corneal buttons.

Authors:  B E van Gelderen; A Van der Lelij; W F Treffers; R van der Gaag
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

Review 7.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

8.  Morphometric analysis of postoperative corneal neovascularization after high-risk keratoplasty: herpetic versus non-herpetic disease.

Authors:  Amadeus E Altenburger; Björn Bachmann; Berthold Seitz; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-15       Impact factor: 3.117

Review 9.  Ocular herpes simplex virus type 1: is the cornea a reservoir for viral latency or a fast pit stop?

Authors:  David P Kennedy; Christian Clement; Richard L Arceneaux; Partha S Bhattacharjee; Tashfin S Huq; James M Hill
Journal:  Cornea       Date:  2011-03       Impact factor: 2.651

10.  Corneal latency and transmission of herpes simplex virus-1.

Authors:  Asim V Farooq; Deepak Shukla
Journal:  Future Virol       Date:  2011-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.